Compare Mesoblast Limited (MESO) vs Under Armour Inc Class A (UAA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Under Armour Inc Class A — how do they compare? Mesoblast Limited trades at $16.38 (market cap $2.17B), while Under Armour Inc Class A trades at $7.3 (market cap $3.07B). The key difference: Under Armour Inc Class A is the larger of the two by market cap, and Under Armour Inc Class A is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.
| MESO | UAA | |
|---|---|---|
Market Cap | $2.17B | $3.07B |
Sector | Technology | Consumer Cyclical |
52-Week High | $20.96 | $8.14 |
52-Week Low | $12.88 | $4.17 |
Enterprise Value | $2.17B | $4.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →
